Company: SMNR
Filing Date: 2025-08-13
Form Type: 424B3
Source: 0001193125-25-179226
Chunk: 605

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-08-13
Form: 424B3
Chunk 605
---
 applicable requirements of the Sarbanes-Oxley Act and all applicable SEC rules and Nasdaq Listing Rules. New Semnur intends to comply with future requirements to the extent they become applicable to New Semnur. Compensation Committee New Semnur’s compensation committee will consist of Dorman Followwill and Yue Alexander Wu, Ph.D., with Yue Alexander Wu, Ph.D. serving as the chairperson of the committee. Dorman Followwill and Yue Alexander Wu, Ph.D. will each satisfy the independence requirements under the Nasdaq Listing Rules. Each of the members of the compensation committee will be a non-employeedirector as defined in Rule 16b-3promulgated under the Exchange Act and will satisfy Nasdaq independence requirements. The compensation committee will act on behalf of the New Semnur Board to fulfill the New Semnur Board’s responsibilities in overseeing the company’s compensation policies, plans and programs; and in reviewing and determining the compensation to be paid to the executive officers and non-employeedirectors of New Semnur. The responsibilities of the compensation committee are included in its written charter. The compensation committee’s responsibilities will include, among others:

| • |     | reviewing, modifying and approving (or, if it deems appropriate, making recommendations to the New Semnur Board                                                                                                                      
 regarding) New Semnur’s overall compensation strategy and policies, to assure that they promote stockholder interests and support the Company’s strategic and tactical objectives, and that they provide for appropriate rewards and 
 incentives for the Company’s management and employees;                                                                                                                                                                               |

| • |     | reviewing, modifying and approving corporate performance goals and objectives relevant to the compensation of New 
 Semnur’s executive officers and other senior management;                                                          |

| • |     | determining and approving (or, if it deems appropriate, recommending to the New Semnur Board for determination                                                                                                                                   
 and approval) the compensation and terms of employment of New Semnur’s Chief Executive Officer, including seeking to achieve an appropriate level of risk and reward in determining the long-term incentive component of the compensation of the 
 Chief Executive Officer;                                                                                                                                                                                                                         |

382

| • |     | determining and approving (or, if it deems appropriate, recommending to the New Semnur Board for determination                    
 and approval) the compensation and terms of employment of New Semnur’s executive officers and other members of senior management; |

| • |     | reviewing and approving (or, if it deems appropriate, making recommendations to the